SCHEDULE: Sharpe Boosts Conexeu Stake to 5.2% Post-Milestone

Jeffrey Sharpe increased his beneficial ownership of Conexeu Sciences Inc. common stock to 5.2% following the exercise of performance warrants tied to a market capitalization milestone.

Summary

• Jeffrey Sharpe, a director of Conexeu Sciences Inc., has amended his Schedule 13D filing to reflect an increase in his beneficial ownership of the company's common stock.
• As of September 14, 2026, Mr. Sharpe beneficially owns 1,500,000 shares of common stock, representing approximately 5.2% of the outstanding shares.
• This increase is due to the exercise of 500,000 performance warrants on September 14, 2026, which vested upon the company achieving a market capitalization of $80,000,000 or greater for at least 20 consecutive trading days.
• The exercise price for these warrants was $0.001 per share, resulting in aggregate proceeds of $500.00 to the issuer.
• The filing also notes the prior exercise of 500,000 warrants on May 22, 2026, which vested upon the company's listing on the Nasdaq.
• Mr. Sharpe holds these shares for investment purposes and reserves the right to adjust his holdings based on market conditions.
• The filing excludes 500,000 performance warrants that are not yet vested and will not vest until the submission of a 510(k) application to the FDA.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as moderately positive, reflecting an increase in beneficial ownership and the achievement of a significant corporate milestone, though it primarily details routine warrant exercises and compensation arrangements.

Positives

• Increase in beneficial ownership by a key insider (Director Jeffrey Sharpe) to 5.2%.
• Achievement of a significant corporate milestone: market capitalization of $80,000,000 or greater for at least 20 consecutive trading days, leading to warrant vesting.
• Successful exercise of performance warrants, indicating progress towards company goals.
• The company received $1,000 in aggregate proceeds from the exercise of these warrants.

Negatives

• The filing primarily details routine warrant exercises and compensation arrangements, rather than significant new strategic developments.
• A substantial portion of performance warrants (500,000) remain unvested, contingent on future regulatory approval (510(k) submission).

Risks

• The 500,000 unvested performance warrants are contingent on the successful submission of a 510(k) application to the FDA, which carries inherent regulatory risks.
• Future acquisition or disposition of shares by Mr. Sharpe could impact share price depending on market conditions and transaction size.
• The company's reliance on achieving specific market capitalization milestones for warrant vesting highlights a potential sensitivity to stock performance.

Future Outlook

The filing indicates that 500,000 performance warrants remain unvested and will vest upon the submission of a 510(k) application to the U.S. Food and Drug Administration. The Reporting Person reserves the right to formulate other plans or make other proposals regarding his interest in the Issuer, including potential acquisitions or dispositions of securities based on market conditions.

Management Comments

• The Reporting Person currently holds the shares of Common Stock and the Performance Warrants for investment purposes.
• The Reporting Person reserves the right to formulate other plans or make other proposals and take other actions with respect to his interest in the Issuer.
• Depending on market conditions and other factors, the Reporting Person may acquire or dispose of securities of the Issuer as the Reporting Person may deem appropriate, whether in open market purchases or sales, privately negotiated transactions or otherwise.
• The Reporting Person continues to evaluate numerous potential transactions and in connection therewith may exchange shares of Common Stock for other assets or may sell shares of Common Stock to increase his cash position.
• The Reporting Person may also reconsider and change his plans or proposals relating to the foregoing.

Industry Context

StockSavvy.ai notes that this filing pertains to a Schedule 13D amendment, which is typical for significant beneficial owners increasing their stake or changing their investment intent. The milestones achieved (Nasdaq listing, market cap threshold) are common indicators of progress for early-stage biotech or science companies. The reliance on FDA 510(k) submission for further warrant vesting is a critical factor for companies in the medical device or diagnostics sector.

Comparison to Industry Standards

• The structure of performance warrants tied to specific corporate milestones (listing, market cap, regulatory submission) is a common compensation and incentive mechanism in the biotechnology and life sciences industries.
• Companies like Moderna or BioNTech have utilized similar equity-based incentives tied to clinical trial progress and regulatory approvals.
• The exercise price of $0.001 per share is exceptionally low, often seen in early-stage private placements or founder/consultant agreements before significant valuation increases.

Related Party Transactions

• Consulting services agreement between Conexeu Sciences Inc. and 1036030 B.C. Ltd. (a company solely owned by Reporting Person, Jeffrey Sharpe) dated May 14, 2025, for which 2,000,000 Performance Warrants were granted.

Stakeholder Impact

• Shareholders: Increased beneficial ownership by a director may be viewed positively, indicating insider confidence. However, potential future sales by the Reporting Person could create selling pressure.
• Employees: The achievement of milestones and warrant vesting can be seen as a positive indicator of company progress, potentially boosting morale.
• Creditors: No direct impact mentioned.
• Suppliers: No direct impact mentioned.

Next Steps

• Submission of a 510(k) application to the U.S. Food and Drug Administration, which will trigger the vesting of the remaining 500,000 performance warrants.
• Reporting Person may acquire or dispose of additional securities of the Issuer.
• Reporting Person may exchange shares of Common Stock for other assets or sell shares to increase cash position.

Key Dates

Recommendation

The filing is an amendment to a Schedule 13D, primarily detailing the exercise of vested warrants by a director and an increase in his beneficial ownership to 5.2%. While the achievement of a market capitalization milestone is positive, the core of the filing relates to compensation and existing arrangements rather than new strategic initiatives or significant financial performance changes that would warrant a buy or sell recommendation. The future outlook is contingent on regulatory approval for remaining warrants. Therefore, a 'hold' is appropriate pending further material developments.

Keywords

Schedule 13D, Beneficial Ownership, Performance Warrants, Market Capitalization, Nasdaq Listing, FDA 510(k), Director Compensation, Insider Trading